Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells

Biochimie

Volumn 94, Issue 8, 2012, Pages 1812-1820

  Montenegro, Cyntia F ^a   Salla Pontes, Carmen L ^a   Ribeiro, Juliana U ^a   MacHado, Aline Z ^a   Ramos, Rafael F ^a   Figueiredo, Camila C ^b   Morandi, Verônica ^b   Selistre De Araujo, Heloisa S ^a  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cell adhesion; Disintegrin; Integrin; MMP; Tumor microenvironment; VEGF; VEGFR

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; ARGINYLGLYCYLASPARTIC ACID; COLLAGEN TYPE 1; DISBA 01; DISINTEGRIN; GELATINASE A; GELATINASE B; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS INHIBITION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; BOTHROPS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; COLLAGEN TYPE I; DISINTEGRINS; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; PROTEIN BINDING; SIGNAL TRANSDUCTION; SNAKE VENOMS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

BOTHROPS ALTERNATUS;

EID: 84862899614     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.04.020     Document Type: Article

References (65)

1. P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, Nat. Med. 12 (2006) 895-904.
2. C.H. Stuelten, S. DaCosta Byfield, P.R. Arany, T.S. Karpova, W.G. Stetler-Stevenson, A.B. Roberts, Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta, J. Cell Sci. 118 (2005) 2143-2153.
3. S. Loffek, P. Zigrino, P. Angel, B. Anwald, T. Krieg, C. Mauch, High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms, J. Invest. Dermatol. 124 (2005) 638-643.
4. L. Li, B. Dragulev, P. Zigrino, C. Mauch, J.W. Fox, The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo, Int. J. Cancer 125 (2009) 1796-1804.
5. V.J. Coulson-Thomas, T.F. Gesteira, Y.M. Coulson-Thomas, C.M. Vicente, I.L. Tersariol, H.B. Nader, L. Toma, Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-beta, and extracellular matrix down-regulation, Exp. Cell Res. 316 (2010) 3207-3226.
6. R.E. Bachelder, M.A. Wendt, A.M. Mercurio, Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4, Cancer Res. 62 (2002) 7203-7206.
7. A.M. Mercurio, E.A. Lipscomb, R.E. Bachelder, Non-angiogenic functions of VEGF in breast cancer, J. Mammary Gland Biol. Neoplasia 10 (2005) 283-290.
8. M. Shibuya, Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis, J. Biochem. Mol. Biol. 39 (2006) 469-478.
9. A.M. Mercurio, R.E. Bachelder, R.C. Bates, J. Chung, Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin, Semin. Cancer Biol. 14 (2004) 115-122.
10. A.K. Olsson, A. Dimberg, J. Kreuger, L. Claesson-Welsh, VEGF receptor signalling - in control of vascular function, Nat. Rev. Mol. Cell Biol. 7 (2006) 359-371.
11. L.M. Vecchiarelli-Federico, D. Cervi, M. Haeri, Y. Li, A. Nagy, Y. Ben-David, Vascular endothelial growth factor-a positive and negative regulator of tumor growth, Cancer Res. 70 (2010) 863-867.
12. M. Shibuya, L. Claesson-Welsh, Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis, Exp. Cell Res. 312 (2006) 549-560.
13. A. Grothey, E. Galanis, Targeting angiogenesis: progress with anti-VEGF treatment with large molecules, Nat. Rev. Clin. Oncol. 6 (2009) 507-518.
14. L.M. Ellis, D.J. Hicklin, Pathways mediating resistance to vascular endothelial growth factor-targeted therapy, Clin. Cancer Res. 14 (2008) 6371-6375.
15. J.M. Ebos, C.R. Lee, R.S. Kerbel, Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy, Clin. Cancer Res. 15 (2009) 5020-5025.
16. J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities, Nat. Rev. Cancer 10 (2010) 9-22.
17. C.K. Miranti, J.S. Brugge, Sensing the environment: a historical perspective on integrin signal transduction, Nat. Cell Biol. 4 (2002) E83-E90.
18. H. Jin, J. Varner, Integrins: roles in cancer development and as treatment targets, Br. J. Cancer 90 (2004) 561-565.
19. K.Z. Olfa, L. Jose, D. Salma, B. Amine, S.A. Najet, A. Nicolas, L. Maxime, Z. Raoudha, M. Kamel, M. Jacques, S. Jean-Marc, A. Mohamed el, M. Naziha, Lebestatin, a disintegrin from Macrovipera venom, inhibits integrin-mediated cell adhesion, migration and angiogenesis, Lab. Invest. 85 (2005) 1507-1516.
20. C.R. Cooper, C.H. Chay, K.J. Pienta, The role of alpha(v)beta(3) in prostate cancer progression, Neoplasia 4 (2002) 191-194.
21. O.H. Ramos, A. Kauskot, M.R. Cominetti, I. Bechyne, C.L. Salla Pontes, F. Chareyre, J. Manent, R. Vassy, M. Giovannini, C. Legrand, H.S. Selistre-de- Araujo, M. Crepin, A. Bonnefoy, A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis, Clin. Exp. Metastasis 25 (2008) 53-64.
22. R.S. Yang, C.H. Tang, W.J. Chuang, T.H. Huang, H.C. Peng, T.F. Huang, W.M. Fu, Inhibition of tumor formation by snake venom disintegrin, Toxicon 45 (2005) 661-669.
23. M.S. Aguzzi, P. Fortugno, C. Giampietri, G. Ragone, M.C. Capogrossi, A. Facchiano, Intracellular targets of RGDS peptide in melanoma cells, Mol. Cancer 9 (2010) 84.
24. S. Hariharan, D. Gustafson, S. Holden, D. McConkey, D. Davis, M. Morrow, M. Basche, L. Gore, C. Zang, C.L. O'Bryant, A. Baron, D. Gallemann, D. Colevas, S.G. Eckhardt, Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors, Ann. Oncol. 18 (2007) 1400-1407.
25. L. Oliveira-Ferrer, J. Hauschild, W. Fiedler, C. Bokemeyer, J. Nippgen, I. Celik, G. Schuch, Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway, J. Exp. Clin. Cancer Res. 27 (2008) 86.
26. N. Gomes, J. Vassy, C. Lebos, B. Arbeille, C. Legrand, F. Fauvel-Lafeve, Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists, Clin. Exp. Metastasis 21 (2004) 553-561.
27. B. Felding-Habermann, T.E. O'Toole, J.W. Smith, E. Fransvea, Z.M. Ruggeri, M.H. Ginsberg, P.E. Hughes, N. Pampori, S.J. Shattil, A. Saven, B.M. Mueller, Integrin activation controls metastasis in human breast cancer, Proc. Natl. Acad. Sci. U S A 98 (2001) 1853-1858.
28. M. Trikha, Y.A. De Clerck, F.S. Markland, Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis, Cancer Res. 54 (1994) 4993-4998.
29. O.H. Ramos, C.H. Terruggi, J.U. Ribeiro, M.R. Cominetti, C.C. Figueiredo, M. Berard, M. Crepin, V. Morandi, H.S. Selistre-de-Araujo, Modulation of in vitro and in vivo angiogenesis by alternagin-C, a disintegrin-like protein from Bothrops alternatus snake venom and by a peptide derived from its sequence, Arch. Biochem. Biophys. 461 (2007) 1-6.
30. C.H. Yeh, H.C. Peng, R.S. Yang, T.F. Huang, Rhodostomin, a snake venom dis-integrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells, Mol. Pharmacol. 59 (2001) 1333-1342.
31. V. Golubkov, D. Hawes, F.S. Markland, Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom, Angiogenesis 6 (2003) 213-224.
32. S.I. Kim, K.S. Kim, H.S. Kim, D.S. Kim, Y. Jang, K.H. Chung, Y.S. Park, Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors, Cancer Res. 63 (2003) 6458-6462.
33. J.J. Calvete, J.W. Fox, A. Agelan, S. Niewiarowski, C. Marcinkiewicz, The presence of the WGD motif in CC8 heterodimeric disintegrin increases its inhibitory effect on alphaII(b)beta3, alpha(v)beta3, and alpha5beta1 integrins, Biochemistry 41 (2002) 2014-2021.
34. M.C. Brown, I. Staniszewska, L. Del Valle, G.P. Tuszynski, C. Marcinkiewicz, Angiostatic activity of obtustatin as a1b1 integrin inhibitor in experimental melanoma growth, Int. J. Cancer 123 (2008) 2195-2203.
35. P. Juárez, G. Bolás, F.F. Rezende, J.J. Calvete, J.A. Eble, Recombinant expression in human cells of active integrin α1β1- blocking RTS-disintegrin jerdostatin, Toxicon 56 (2010) 1052-1058.
36. M.C. Brown, J.A. Eble, J.J. Calvete, C. Marcinkiewicz, Structural requirements of KTS-disintegrins for inhibition of α1β1 integrin, Biochem. J. 417 (2009) 95-101.
37. A. Kauskot, M.R. Cominetti, O.H. Ramos, I. Bechyne, J.M. Renard, M.F. Hoylaerts, M. Crepin, C. Legrand, H.S. Selistre-de-Araujo, A. Bonnefoy, Hemostatic effects of recombinant DisBa-01, a disintegrin from Bothrops alternatus, Front. Biosci. 13 (2008) 6604-6616.
38. H.S. Selistre-de-Araujo, C.L.S. Pontes, C.F. Montenegro, A.C.B.M. Martin, Snake venom disintegrins and cell migration, Toxins 2 (2010) 2606-2621.
39. M.R. Cominetti, A.C.B.M. Martin, J.U. Ribeiro, I. Djaafri, F. Fauvel-Lafève, M. Crépin, H.S. Selistre-de-Araujo, Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen under dynamic flow conditions, Biochimie 91 (2009) 1045-1052.
40. R.M. Barstad, H.E. Roald, Y. Cui, V.T. Turitto, K.S. Sakariassen, A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses, Arterioscler Thromb. 14 (1994) 1984-1991.
41. M.R. Cominetti, C.H. Terruggi, O.H. Ramos, J.W. Fox, A. Mariano-Oliveira, M.S. De Freitas, C.C. Figueiredo, V. Morandi, H.S. Selistre-de-Araujo, Alternagin- C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro, J. Biol. Chem. 279 (2004) 18247-18255.
42. C.C. Kumar, Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis, Curr. Drug Targets 4 (2003) 123-131.
43. J.G. Schneider, S.R. Amend, K.N. Weilbaecher, Integrins and bone metastasis: integrating tumor cell and stromal cell interactions, Bone 48 (2011) 54-65.
44. G.E. Davis, D.R. Senger, Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization, Circ. Res. 97 (2005) 1093-1107.
45. T. van Wieringen, S. Kalamajski, A. Liden, D. Bihan, B. Guss, D. Heinegard, R.W. Farndale, K. Rubin, The streptococcal collagen-binding protein CNE specifically interferes with alphaVbeta3-mediated cellular interactions with triple helical collagen, J. Biol. Chem. 285 (2010) 35803-35813.
46. T. Hayashida, H. Jinno, Y. Kitagawa, M. Kitajima, Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis, J. Oncol. 2011 (2011) 591427.
47. A.R. Reynolds, Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer, Dose Response 8 (2009) 253-284.
48. L. Veschini, D. Belloni, C. Foglieni, M.G. Cangi, M. Ferrarini, F. Caligaris-Cappio, E. Ferrero, Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib, Blood 109 (2007) 2565-2570.
49. A.R. Reynolds, I.R. Hart, A.R. Watson, J.C. Welti, R.G. Silva, S.D. Robinson, G. Da Violante, M. Gourlaouen, M. Salih, M.C. Jones, D.T. Jones, G. Saunders, V. Kostourou, F. Perron-Sierra, J.C. Norman, G.C. Tucker, K.M. Hodivala-Dilke, Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors, Nat. Med. 15 (2009) 392-400.
50. S.M. Weis, D.G. Stupack, D.A. Cheresh, Agonizing integrin antagonists, Cancer Cell 15 (2009) 359-361.
51. F. Lebrin, M. Deckers, P. Bertolino, P. Ten Dijke, TGF-beta receptor function in the endothelium, Cardiovasc. Res. 65 (2005) 599-608.
52. R. Polanowska-Grabowska, J.M. Gibbins, A.R. Gear, Platelet adhesion to collagen and collagen-related peptide under flow: roles of the [alpha]2[beta]1 integrin, GPVI, and Src tyrosine kinases, Arterioscler Thromb. Vasc. Biol. 23 (2003) 1934-1940.
53. S. Jain, J. Harris, J. Ware, Platelets: linking hemostasis and cancer, Arterioscler Thromb. Vasc. Biol. 30 (2010) 2362-2367.
54. M. Franco, P. Roswall, E. Cortez, D. Hanahan, K. Pietras, Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression, Blood 118 (2011) 2906-2917.
55. B. Tavora, S. Batista, L.E. Reynolds, S. Jadeja, S. Robinson, V. Kostourou, I. Hart, M. Fruttiger, M. Parsons, K.M. Hodivala-Dilke, Endothelial FAK is required for tumour angiogenesis, EMBO Mol. Med. 2 (2010) 516-528.
56. D.J. Hicklin, L.M. Ellis, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol. 23 (2005) 1011-1027.
57. L.M. Ellis, D.J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat. Rev. Cancer 8 (2008) 579-591.
58. O. Casanovas, D.J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell 8 (2005) 299-309.
59. C. Stockmann, A. Doedens, A. Weidemann, N. Zhang, N. Takeda, J.I. Greenberg, D.A. Cheresh, R.S. Johnson, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis, Nature 456 (2008) 814-818.
60. S. Guo, R.R. Gonzalez-Perez, Notch, IL-1 and Leptin Crosstalk Outcome (NILCO) is critical for Leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer, PLoS One 6 (2011) e21467.
61. R. Susarla, A.M. Gonzalez, J.C. Watkinson, M.C. Eggo, Expression of receptors for VEGFS on normal human thyroid follicular cells and their role in follicle formation, J. Cell Physiol. (2011).
62. S.H. Lee, Y.J. Lee, C.H. Song, Y.K. Ahn, H.J. Han, Role of FAK phosphorylation in hypoxia-induced hMSCS migration: involvement of VEGF as well as MAPKS and eNOS pathways, Am. J. Physiol. Cell Physiol. 298 (2010) C847-C856.
63. V.W. van Hinsbergh, M.A. Engelse, P.H. Quax, Pericellular proteases in angiogenesis and vasculogenesis, Arterioscler Thromb. Vasc. Biol. 26 (2006) 716-728.
64. C. Lopez-Otin, L.M. Matrisian, Emerging roles of proteases in tumour suppression, Nat. Rev. Cancer 7 (2007) 800-808.
65. S. Schmitmeier, F.S. .Markland, M.R. Ritter, D.E. Sawcer, T.C. Chen, Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro, Cell Commun. Adhes. 10 (2003) 1-16.